Jarrod Longcor
Insider
First SEC filing: March 5, 2021 · Latest: March 5, 2021
Insider at
Insider transactions
2 buys (P)
0 sells (S)
Net: $25,258
Avg return of open purchases vs now: 8279.0%
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| July 7, 2026 | CLRB | A | 118,000 | · | · | 118,000 Direct | · | Acquired | (price as of 2026-10-05) |
| May 7, 2026 | CLRB | P | 26,040 | $0.01 | $260 | 36,149 Direct | +257.59% | Acquired | 16600.0% (price as of 2026-10-05) |
| May 7, 2026 | CLRB | P | 8,680 | $2.88 | $24,998 | 20,451 Direct | +73.74% | Acquired | -42.0% (price as of 2026-10-05) |
| July 2, 2025 | CLRB | P | 10,000 | $0.01 | $100 | 10,000 Direct | · | Acquired | 16600.0% (price as of 2026-10-05) |
| July 2, 2025 | CLRB | P | 10,000 | $4.99 | $49,900 | 12,768 Direct | +361.27% | Acquired | -66.5% (price as of 2026-10-05) |
| Feb. 14, 2025 | CLRB | A | 500,000 | · | · | 500,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Jan. 10, 2025 | CLRB | P | 30,000 | $0.28 | $8,400 | 83,141 Direct | +56.45% | Acquired | -80.1% (price as of 2026-10-05) |
| June 14, 2024 | CLRB | A | 500,000 | · | · | 500,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Dec. 8, 2023 | CLRB | A | 42,927 | · | · | 53,141 Direct | +420.28% | Acquired | (price as of 2026-10-05) |
| June 23, 2023 | CLRB | A | 144,000 | · | · | 144,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Jan. 17, 2023 | CLRB | A | 144,000 | · | · | 144,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Jan. 25, 2022 | CLRB | A | 475,000 | · | · | 475,000 Direct | · | Acquired | (price as of 2026-10-05) |
| March 4, 2021 | CLRB | A | 450,000 | · | · | 450,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Dec. 28, 2020 | CLRB | P | 29,630 | $1.35 | $40,000 | 102,148 Direct | +40.86% | Acquired | -99.6% (price as of 2026-10-05) |
| June 5, 2020 | CLRB | P | 32,609 | $0.01 | $326 | 32,609 Direct | · | Acquired | -44.3% (price as of 2026-10-05) |
| June 5, 2020 | CLRB | P | 65,218 | $1.14 | $74,349 | 72,518 Direct | +893.40% | Acquired | -99.5% (price as of 2026-10-05) |
| Feb. 3, 2020 | CLRB | A | 40,000 | · | · | 40,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Feb. 3, 2020 | CLRB | A | 40,000 | $2.71 | $108,400 | 40,000 Direct | · | Acquired | -99.8% (price as of 2026-10-05) |
| Feb. 28, 2019 | CLRB | P | 100 | $2.00 | $200 | 7,300 Direct | +1.39% | Acquired | -99.7% (price as of 2026-10-05) |
| Jan. 17, 2019 | CLRB | A | 30,000 | · | · | 30,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Oct. 12, 2018 | CLRB | A | 63,000 | · | · | 63,000 Direct | · | Acquired | (price as of 2026-10-05) |
| Aug. 16, 2018 | CLRB | P | 500 | $2.71 | $1,355 | 7,200 Direct | +7.46% | Acquired | -99.8% (price as of 2026-10-05) |
| March 13, 2018 | CLRB | S 10b5-1 | 13,000 | $1.18 | $15,340 | 67,000 Direct | -16.25% | Disposed | -100.0% (price as of 2026-10-05) |
| Sept. 18, 2017 | CLRB | A | 25,000 | · | · | 25,000 Direct | · | Acquired | (price as of 2026-10-05) |
| April 18, 2017 | CLRB | A | 80,000 | · | · | 80,000 Direct | · | Acquired | (price as of 2026-10-05) |
| July 15, 2016 | CLRB | A | 75,000 | · | · | 75,000 Direct | · | Acquired | (price as of 2026-10-05) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| July 7, 2026 | CLRB | Stock option (right to buy) | Common stock | $3.14 | May 28, 2036 | 118,000 | Acquired |
| May 7, 2026 | CLRB | Warrants | Common Stock | $2.88 | · | 26,040 | Acquired |
| July 2, 2025 | CLRB | Warrants | Common Stock | $5.25 | July 2, 2030 | 10,000 | Acquired |
| Feb. 14, 2025 | CLRB | Stock option (right to buy) | Common Stock | $0.29 | Feb. 14, 2035 | 500,000 | Acquired |
| June 14, 2024 | CLRB | Stock option (right to buy) | Common Stock | $2.65 | Dec. 15, 2033 | 500,000 | Acquired |
| June 23, 2023 | CLRB | Stock option (right to buy) | Common Stock | $1.68 | Jan. 17, 2033 | 144,000 | Acquired |
| Jan. 17, 2023 | CLRB | Stock option (right to buy) | Common Stock | $1.68 | Jan. 17, 2033 | 144,000 | Acquired |
| Jan. 25, 2022 | CLRB | Stock option (right to buy) | Common Stock | $0.55 | Jan. 25, 2032 | 475,000 | Acquired |
| March 4, 2021 | CLRB | Stock option (right to buy) | Common Stock | $1.74 | March 4, 2021 | 450,000 | Acquired |
| June 5, 2020 | CLRB | Series H Warrants | Common Stock | $1.21 | June 5, 2025 | 32,609 | Acquired |
| Feb. 3, 2020 | CLRB | Stock option (right to buy) | Common Stock | $2.71 | Feb. 3, 2030 | 40,000 | Acquired |
| Jan. 17, 2019 | CLRB | Stock option (right to buy) | Common Stock | $1.99 | Jan. 17, 2029 | 30,000 | Acquired |
| Oct. 12, 2018 | CLRB | Stock option (right to buy) | Common Stock | $2.61 | Oct. 12, 2028 | 63,000 | Acquired |
| Sept. 18, 2017 | CLRB | Employee Stock Option (right to buy) | Common Stock | $1.83 | Sept. 18, 2027 | 25,000 | Acquired |
| July 15, 2016 | CLRB | Employee Stock Option (right to buy) | Common Stock | $2.93 | July 15, 2026 | 75,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $500,000 | · | · | $1,230,000 | $100,000 | · | · | $1,830,000 |
| 2023 | $480,000 | · | $113,758 | $394,560 | $288,000 | · | $86,242 | $1,362,560 |
| 2022 | $450,000 | · | · | $206,435 | $175,320 | · | · | $831,755 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.